RESONANCE Health, which develops non-invasive liver scanners, will collaborate with CSIRO to enhance its ability to measure liver fibrosis.
The company develops and delivers non- invasive image analysis technologies used by clinicians globally for accurate assessment of their patients’ conditions. These include FerriScan for measuring liver iron overload and HepaFat-Scan to measure liver fat.
It has also developed a prototype for a non-invasive fibrosis measurement that distinguishes between low and high fibrosis scores in a patient cohort with Hepatitis C.
The collaboration with the CSIRO will allow Resonance Health to apply the organisation’s expertise to its product development.
The company will be working together with CSIRO’s Biomedical Imaging Group led by Dr Olivier Salvado. Within the liver fibrosis project CSIRO will use a number of software components and algorithms that are packaged within an image processing and viewing platform, and cloud-based analysis platform.
On CSIRO’s part, the partnership will provide it with the opportunity to translate its research to the clinic, benefiting doctors and patients.